Poniard Pharmaceuticals Reports Q4 EPS $(0.11)

Loading...
Loading...
Poniard Pharmaceuticals, Inc.
PARD
today reported financial results for the fourth quarter. The Company reported a net loss of $5.2 million ($0.11 diluted loss per share on a loss applicable to common shares of $5.2 million) for the quarter ended December 31, 2010, compared with a net loss of $13.2 million ($0.36 diluted loss per share on a loss applicable to common shares of $13.3 million) for the quarter ended December 31, 2009.
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBiotechnologyHealth Care
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...